Related Experiment Video

Updated: May 5, 2026

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

12.5K

[Multiple myeloma]

Masahiro Abe1

  • 1Department of Medicine and Bioregulatory Sciences, University of Tokushima Graduate School of Medicine.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|May 13, 2009
PubMed

Insights

Multiple myeloma bone disease management involves bisphosphonates and bortezomib. Understanding their long-term effects and risks, like osteonecrosis of the jaw, is crucial for effective treatment.

Area of Science:

  • Oncology
  • Bone Biology
  • Pharmacology

Context:

  • Multiple myeloma frequently leads to severe bone complications such as pain, fractures, and hypercalcemia.
  • Bisphosphonates are standard treatments for preventing skeletal-related events in myeloma patients.
  • Long-term bisphosphonate efficacy and safety, particularly concerning osteonecrosis of the jaw (ONJ), require further investigation.

Purpose:

  • To evaluate the roles of bone-targeting agents in managing myeloma bone disease.
  • To clarify the benefits and risks associated with bisphosphonates and proteasome inhibitors like bortezomib.
  • To optimize the use of these agents by mitigating adverse effects.

Summary:

  • Bisphosphonates inhibit osteoclast activity, reducing bone destruction in multiple myeloma.
  • The proteasome inhibitor bortezomib shows potential anabolic effects, promoting bone formation.
  • Concerns exist regarding long-term bisphosphonate use, specifically the risk of osteonecrosis of the jaw.

Impact:

  • Improved understanding of bone-targeting therapies for multiple myeloma.
  • Guidance on balancing the benefits of bisphosphonates and bortezomib against potential side effects.
  • Potential for enhanced treatment strategies to preserve bone health in myeloma patients.

More Related Videos

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.1K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

5.7K

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
13.2K
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
20